Acrivon Therapeutics, Inc.
ACRV
$2.05
-$0.06-2.62%
NASDAQ
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | -25.41% | -24.20% | -15.09% | -3.78% | 0.86% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -17.58% | -8.12% | -19.39% | -21.69% | 5.65% |
| Operating Income | 17.58% | 8.12% | 19.39% | 21.69% | -5.65% |
| Income Before Tax | 14.48% | 3.24% | 16.85% | 18.75% | -11.75% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | 14.48% | 3.24% | 16.85% | 18.75% | -11.75% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 14.48% | 3.24% | 16.85% | 18.75% | -11.75% |
| EBIT | 17.58% | 8.12% | 19.39% | 21.69% | -5.65% |
| EBITDA | 18.15% | 8.58% | 19.86% | 22.30% | -5.21% |
| EPS Basic | 21.40% | 4.19% | 17.74% | 19.70% | -4.98% |
| Normalized Basic EPS | 21.39% | 4.18% | 27.80% | 19.72% | -4.95% |
| EPS Diluted | 21.40% | 4.19% | 17.74% | 19.70% | -4.98% |
| Normalized Diluted EPS | 21.39% | 4.18% | 27.80% | 19.72% | -4.95% |
| Average Basic Shares Outstanding | 8.79% | 0.98% | 1.09% | 1.20% | 6.45% |
| Average Diluted Shares Outstanding | 8.79% | 0.98% | 1.09% | 1.20% | 6.45% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |